Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...